Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 294-301

  Russo, Giuseppina T ^a   Horvath, Kathleen V ^b   Di Benedetto, Antonino ^a   Giandalia, Annalisa ^a   Cucinotta, Domenico ^a   Asztalos, Bela ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b TUFTS UNIVERSITY   (United States)

Author keywords

CETP; Diabetes; HDL subpopulations; Menopause; Women

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NY ESO 1 ANTIGEN; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; BLOOD GLUCOSE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, HDL; MENOPAUSE; MIDDLE AGED; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 77952418994     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.11.011     Document Type: Article

References (44)

1. Raza J.A., Reinhart R.A., Movahed A. Ischemic heart disease in women and the role of hormone therapy. Int J Cardiol 2004, 96:7-19.
2. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997, 95:252-264.
3. Sowers J.R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998, 158:617-621.
4. Kannel W.B., Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155:57-61.
5. Asztalos B.F., Schaefer E.J. HDL in atherosclerosis: actor or bystender?. Atherosclerosis 2003, 4(Suppl.):21-29.
6. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
7. Taskinen M.R. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
8. Barbaras R., Puchois P., Fruchart J.C., Ailhaud G. Cholesterol efflux from cultured adipose tissue cells is mediated by LpA-I particles but not by LpA-I:A-II particles. Biochem Biophys Res Commun 1987, 1:63.
9. Asztalos B., Sloop C.H., Wong L., et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169:291-300.
10. Asztalos B.F., Roheim P.S., Milani R.L., et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2670-2676.
11. Heller D.A., de Faire U., Pedersen N.L., Dahlen G., McClearn G.E. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993, 328:1150-1156.
12. Boekholdt S.M., Sacks F.M., Jukema J.W., et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005, 111:278-287.
13. Brousseau M.E., O'Connor J.J., Ordovas J.M., et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002, 22:1148-1154.
14. Ordovas J.M., Cupples L.A., Corella D., et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000, 20:1323-1329.
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
16. Matthews D.R., Hosker J.P., Rudeenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
17. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma lipoprotein fractions. Clin Chim Acta 1987, 166:1-8.
18. McNamara J.R., Shah P.K., Nakajiam K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
20. Shepherd J. Dyslipidaemia in diabetic patients: time for a rethink. Diabetes Obes Metab 2007, 9:609-616.
21. Buse J.B., Tan M.H., Prince M.J., Erickson P.P. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004, 6:133-156.
22. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
23. Schaefer E.J., Asztalos B.F. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol 2007, 100:25-31.
24. Asztalos B.F., de la Llera-Moya M., Dallal G.E., et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 2005, 46:2246-2253.
25. Asztalos B.F., Schaefer E.J., Horvath K.V., et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res 2007, 48:592-599.
26. Ballantyne F.C., Clark R.S., Simpson H.S., Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 1982, 31:433-437.
27. Laakso M., Voutilainen E., Pyorala K., Sarlund H. Association of low HDL and HDL2 cholesterol with coronary heart disease in non-insulin-dependent diabetics. Arteriosclerosis 1985, 5:653-658.
28. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991, 32:383-394.
29. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181-2187.
30. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057-1064.
31. Asztalos B.F., Batista M., Horvath K.V., et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847-852.
32. Bernard S., Moulin P., Lagrost L., et al. Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J Lipid Res 1998, 39:59-65.
33. Durlach A., Clavel C., Girard-Globa A., Durlach V. Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients. J Clin Endocrinol Metab 1999, 84:3656-3659.
34. Lamon-Fava S., Asztalos B.F., Howard T.D., et al. Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. Clin Endocrinol 2009, 10.1111/j.1365-2265.2009.03644.x.
35. Vohl M.C., Lamarche B., Pascot A., et al. Contribution of the cholesteryl ester transfer protein gene TaqIB polymorphism to the reduced plasma HDL-cholesterol levels found in abdominal obese men with the features of the insulin resistance syndrome. Int J Obes Relat Metab Disord 1999, 23:918-925.
36. Freeman D.J., Griffin B.A., Holmes A.P., et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994, 14:336-344.
37. Heilbronn L.K., Noakes M., Clifton P.M. Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis 2002, 162:419-424.
38. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991, 88:2059-2066.
39. Jensen M.K., Mukamal K.J., Overvad K., Rimm E.B. Alcohol consumption. TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women. Eur Heart J 2008, 29:104-112.
40. Klerkx A.H., Tanck M.W., Kastelein J.J., et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629CA polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003, 12:111-123.
41. Junyent M., Lee Y., Smith C.E., et al. The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesterol ester transfer protein gene. Nutr Metab Cardiovasc Dis 2009, 10.1016/j.numecd.2009.02.010.
42. Schaefer E.J, Asztalos B.F. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 2006, 8:41-49.
43. Asztalos B.F., Horvath K.V., McNamara J.R., et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002, 164:361-369.
44. Davidson M., Ma P., Stein E.A., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002, 89:268-275.